



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280
November 13, 2020

To,
**The Corporate Relations Department,
BSE Ltd.**

Sub: Outcome of Board Meeting held on November 13, 2020.

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. Approved the Standalone and Consolidated unaudited financials for the half year ended 30.09.2020 and took note of the Limited Review Reports issued by the Statutory Auditors.

The financial results and the limited review reports are annexed herewith.

2. Appointed M/s. K B S & Associates, Chartered Accountants as Internal Auditor of the Company for the period of 3 years from FY 2020-21
3. Discussed the Company's foray into the Medical Devices Vertical to expand the existing portfolio of the business. The Board also took note signing of the Commercial Agreement with one of the leading German Testing agency for providing them Laboratory and Testing Services in Biocompatibility and Analytics.

The information required to be submitted in terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015 for Item 2 and 3 above are annexed herewith

The meeting commenced at 4.00 P.M. and concluded at 6:00 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED
Scrip Code: 540729 | Scrip ID: VANTABIO

Zohab

ZOHEB SAYANI
COMPANY SECRETARY



BRIEF PROFILE OF INTERNAL AUDITORS

M/s. K B S & Associates, Chartered Accountants are one of the renowned Chartered Accountants of Hyderabad. They have experience of more than three decades in the field of Statutory Audit, Taxation, Internal Audit, Corporate Finance and management consultancy.

The said firm was previously appointed as the Internal Auditor of the Company for a period of 3 years commencing from FY 2017-18. They are now being re-appointed against as the Internal Auditor of the Company for a period of 3 years commencing from FY 2020-21

FORAYING INTO MEDIAL DEVICES VERTICAL AND SIGNING OF COMMERCIAL AGREEMENT WITH LEADING GERMAN TESTING AGENCY

We are happy to announce that Vanta Bioscience Ltd. ("**Vanta Bio**") has decided to foray into Medical Devices vertical.

In this connection, Vanta Bio has entered into a commercial agreement with one of the leading German Testing agency, wherein the Client has commissioned Vanta Bio to carry out Laboratory Testing Services in Biocompatibility and Analytics. The said agreement is valid for a period of 2 years.

This is a major break through for the Company considering its decision to foray into Medical Devices vertical. This is not only an acknowledgement of the technical capabilities of Vanta Bio, but also validation of the world class services being provided by the Company.

Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition.

In terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015, we hereby submit the following information:

Name of the entity with whom Agreement is signed	Leading German Testing Agency - The name is not being disclosed due to confidentiality clause
--	--

Zohar



Area of Agreement	To carry out Laboratory Testing Services in Biocompatibility and Analytics
Domestic/International	The services will be provided in India
Share Exchange ratio	Not applicable – As this is a service agreement
Scope of Business Operation of Agreement	To carry out Laboratory Testing Services in Biocompatibility and Analytics
Details of Consideration/Monetary Terms	Expected to generate a revenue of Rs. 10-15 Cr approx. over the period of 2 years
Significant Terms And Conditions of Agreement	<ol style="list-style-type: none"> 1. To provide laboratory testing services based on the commercial agreement and requirements from the client 2. Valid for a period of 2 years
Whether Agreement with Related Party/Promoter or Promoter Group	No
Size of the Company	VantaBio is a SME company The client is a renowned testing agency company from Germany
Rationale and Benefit Expected	Over the period of association with the German Major, it will provide good exposure to international regulatory & testing requirements and help the Company to assimilate better testing capabilities, while gaining international recognition.

Zohel



VANTA BIOSCIENCE LIMITED
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003
CIN L74999TG2016PLC109280

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2020

(Rupees. In Lacs)

Sr.No	Particulars	STANDALONE				CONSOLIDATED			
		HALF YEAR ENDED		YEAR ENDED		HALF YEAR ENDED		YEAR ENDED	
		30.09.2020 (Un Audited)	30.09.2019 (Un Audited)	31.03.2020 (Audited)	31.03.2020 (Audited)	30.09.2020 (Un Audited)	30.09.2019 (Un Audited)	31.03.2020 (Audited)	31.03.2020 (Audited)
1	Income								
	Revenue from Operation	527.595	730.07	681.24	1411.31	527.59	733.07	681.24	1414.31
	Other Income	0.000	0.00	10.88	10.88	0.02	0.00	10.99	10.99
	Total Revenue	527.595	730.07	692.12	1422.19	527.61	733.07	692.23	1425.3
2	Expenses								
	a) Cost of material Consumed	52.707	81.46	36.46	117.92	52.71	81.46	36.46	117.92
	b) Employee Benfit Expenses	147.333	237.2	256.79	493.99	147.84	252.54	254.84	507.38
	c) Financial Cost	101.452	97.28	97.55	194.83	101.45	97.28	97.54	194.82
	d) Depreciation and amortization Exp	60.602	40.75	78.14	118.89	60.60	40.75	78.14	118.89
	e) other expenses	152.449	194.63	173.13	367.76	149.04	181.41	170.69	352.1
	Total Expenses	514.543	651.32	642.07	1293.39	511.64	653.44	637.67	1291.11
	Profit/(Loss) from ordinary activities before								
3	Exceptional Items (1-2)	13.052	78.75	50.05	128.80	15.98	79.63	54.56	134.19
4	Exceptional Items Income /(Expenses)	0.000	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before tax (3+4)	13.052	78.75	50.05	128.80	15.98	79.63	54.56	134.19
6	Tax Expenses								
	a) Current Tax	-2.165	(15.17)	(6.47)	(21.64)	(3.51)	(19.14)	(5.24)	(24.38)
	b) MAT Credit Availed	0.000		9.45	9.45	0.00	0.00	9.45	9.45
	c) Deferred Tax	-6.539	(6.09)	(12.72)	(18.81)	(6.54)	(6.09)	(12.72)	(18.81)
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	4.349	57.49	40.31	97.80	5.92	54.40	46.05	100.44
8	Other Comprehensive Income / (expenses) for the year, net of tax	0.000	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) Net of Tax (7+8)	4.349	57.49	40.31	97.80	5.92	54.40	46.05	100.44
10	Paid up Equity share capital (face value of Rs.10/-)	631.200	631.20	631.20	631.20	631.20	631.20	631.20	631.20
11	Reserve excluding Revaluation reserve								
12	Earning per share of (before extra ordinary items) Rs.10 Each (Not Annualised)								
	a) Basic (Rs.)	0.007	0.91	0.64	1.55	0.09	0.86	0.73	1.59
	b) Diluted (Rs.)	0.007	0.91	0.64	1.55	0.09	0.86	0.73	1.59
	Earning per share of after extra ordinary items) Rs.10 Each (Not Annualised)								
	a) Basic (Rs.)	0.007	0.91	0.64	1.55	0.09	0.86	0.73	1.59
	b) Diluted (Rs.)	0.007	0.91	0.64	1.55	0.09	0.86	0.73	1.59

For and on behalf of Board of Directors



Dopesh Raja
Dopesh Raja Mulakala
Managing Director

Place : Hyderabad
Date : 13.11.2020

STATEMENT OF ASSETS & LIABILITIES AS ON 30th SEPTEMBER 2020					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		30.09.2020	31.03.2020	30.09.2020	31.03.2020
		Un Audited	Audited	Un Audited	Audited
A	Equity and Liabilities				
1	EQUITY				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1717.15	1712.80	1721.65	1715.73
	c) Non Controlling/Minority Interest	0.00	0.00	99.08	98.97
	Sub total Equity	2348.35	2344.00	2451.93	2445.90
	LIABILITIES				
2	Non Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	1356.16	1042.72	2024.68	1365.14
	b) Provisions		0.00	0.00	0.00
	c) Deferred tax Liabilities	65.61	59.07	65.61	59.07
	d) Other Non Current Liabilities		0.00	0.00	0.00
	Sub Total -Non Current Liabilities	1421.76	1101.79	2090.28	1424.21
3	Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	140.18	188.40	140.18	188.40
	ii) Trade Payables	50.51	49.07	50.51	49.07
	b) Other Current Liabilities	524.68	469.13	663.75	741.75
	c) Provisions	5.23	6.18	8.37	8.12
	d) Current tax Liabilities(net)		0.00	0.00	0.00
	Sub Total -Non Current Liabilities	720.59	712.79	862.80	987.35
	Total Equity and Liabilities	4490.70	4158.58	5405.01	4857.46
B	ASSETS				
1	Non Current Assets				
	a) Property, Plant and Equipment	1581.82	1589.39	1581.82	1589.39
	b) Capital Work in Progress	0.00		797.92	700.47
	c) Other Intangible assets	587.27	486.23	587.27	486.23
	d) Other Intangible assets under development	0.00	0.00	0.00	0.00
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	300.00	300.00	0.00	0.00
	ii) Loans	0.00	0.00	0.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	35.04	35.04	96.76	96.76
	Sub Total Non-CurrentAssets	2504.13	2410.66	3063.77	2872.85
2	Current Assets				
	a) Inventories	1557.43	1400.73	1557.43	1400.73
	b) Financial Assets				
	i) Investments	0.00	0.00	0.00	0.00
	ii) Trade Receivable	173.43	135.59	176.98	139.15
	iii) Bank, Cash and Cash equivalents	7.97	8.67	142.65	19.51
	iv) Loans & Advances	214.22	170.45	430.44	392.42
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	33.53	32.48	33.74	32.80
	Sub Total Current Assets	1986.57	1747.92	2341.24	1984.61
	Total Assets	4490.70	4158.59	5405.01	4857.45

For and on behalf of Board of Directors

M. Dopesh Raja

Dopesh Raja Mulakala
Managing Director
DIN:01176660



Place : Hyderabad
Date : 13.11.2020

Particulars	(Rupees in Lacs)			
	STANDALONE		CONSOLIDATED	
	For the Half Year ended 30.09.2020	For the Year ended 31.03.2020	For the Half Year ended 30.09.2020	For the Year ended 31.03.2020
A. Cash Flow from Operating Activities				
Profit before exceptional , Extraordinary items and Tax	13.05	128.80	15.98	134
Adjustment for:				
Depreciation	60.60	118.89	60.60	119
Finance Charges	101.45	194.83	101.45	195
Gain/Loss on foreign Exchange fluctuation	-	-	-	-
Sub total	162.05	313.72	162.05	313.71
Operating profit Before Working Capital Changes	175.11	442.52	178.03	447.90
Adjustment for:				
(Increase) /Decrease in Inventories	-156.69	-476.31	(156.69)	(476.31)
(Increase) /Decrease in Trade receivables	-37.84	20.80	(37.84)	17.25
Increase /(Decrease) in trade payable	56.02	205.49	(76.33)	403.31
(Increase) /Decrease Loans & Advances	-44.82	-70.60	(38.96)	(353.05)
(Increase) /Decrease in Current Investment	0.00	195.00	-	195.00
Sub total	-183.32	-125.62	(309.82)	-213.80
Cash Generated from operations	-8.22	316.90	-131.79	234.10
Net Cash Flow from Operating Activities	-8.22	316.90	(131.79)	234.10
B: Cash Flow from Investing Activities				
Purchase of Fixed Assets	-53.03	-34.69	(53.03)	(34.69)
Capital Work In progress	-	-	(198.49)	-700
Capital Work In progress-R&D	(101.04)	-	-	-
proceeds from sale of Fixed Assets	-	-	-	-
Investment in Subsidiaries	-	(100.00)	-	-
Purchase of other Non current Investments	-	-	-	-
Net Cash Flow from Investing Activities	-154.07	-134.69	(251.52)	(735.16)
C: Cash Flow from Financing Activities				
Increase /(Decrease) in Unsecured Loan	-	-	-	110
Increase /(Decrease) in Working capital	-48.22	188.40	(48.22)	128
Increase /(Decrease) in Term Loan	313.43	-173.90	659.53	173.91
Increase /(Decrease) in share capital	-	-	-	-
Increase /(Decrease) in share Premium	-	-	-	-
Finance Charges	-101.45	-194.83	(101.45)	(194.82)
Net Cash Flow from Financing Activities	163.76	-180.33	509.86	217.48
Actual Payment of Income Tax	-2.16	-21.64	(3.41)	(23.54)
D: Net Increase/Decrease in Cash and cash Equivalents	-0.70	-19.76	123.14	-307.12
Opening of Cash & Cash Equivalents	8.67	28.43	19.51	326.63
Closing Balance of Cash & Cash Equivalents	7.97	8.67	142.65	19.51
See accompanying notes to the financial statements As per our report of even date annexed.				
<p>Place : Hyderabad Date : 13.11.2020</p> <p style="text-align: right;">For and on behalf of Board of Directors  Dopesh Raja Mulakala Managing Director DIN:01176660</p> 				

Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November, 2020.
2. The Statutory Auditors have carried out limited review of the Unaudited Results of the company for the half year ended 30.09.2020
3. The statements are prepared in accordance with the requirement of Accounting Standards (AS) specified under section 133 of the Companies Act, 2013 read with rule 7 of the companies (Accounts) Rules, 2014.
4. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
5. Statement of Assets and Liabilities as on 30th September 2020 is enclosed herewith.
6. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
7. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
8. **Impact of Covid-19 on Business of the company**

It is envisaged that impact of the COVID-19 pandemic, including that on financial condition and results of operations, future operations, capital and financial resources, liquidity, assets, internal financial control over financial reporting and disclosure controls and procedures, demand for products/services etc. would not be too significant in case of our company..

Though, there has been a lag in receivables from clients and also in availability of raw material for conducting some specific studies due to restriction placed on movement and transportation. However, there is no long term major impact as such on the overall set up and functioning of the Company as on date.

Further, it is anticipated that with work and transportation related relaxations being notified for various parts of the country and gradual start of economic activities would eventually result in cash flows and availability of raw materials as and when required for continuation of our studies.

9. The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.

M. D. Patel






Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company

**To The Board of Directors of
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Vanta Bioscience Limited ("the Company") for the half year ended on 30th September, 2020 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS


B. V. RAMANA REDDY
M. No: 026967 Partner



UIDN: 20026967AAAAHJ4217

Place: Hyderabad
Date: 13.11.2020



**Independent Auditor's Limited Review Report on unaudited consolidated half yearly
and year to date financial results of the Company**

**To The Board of Directors of
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Vanta Bioscience Limited (“the Parent”) and its subsidiaries (the parent and its subsidiaries together referred as “the Group”) for the half year ended on 30th September, 2020 (“the statement”), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent’s Management and has been approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting Standard 25 “Interim Financial Reporting” (“AS 25”), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Vanta Bioscience Limited- Parent Company
 - b. Vanta Clinical Research Limited- Subsidiary Company
 - c. Vayam Research Solutions Limited-Step Down Subsidiary
5. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

E-mail : mateshca@yahoo.co.in





6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of 2 subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs.1,348.41 Lakhs as at September 30, 2020 and total revenues of Rs.13.00 Lakhs for the half year ended September 30, 2020, total net profit after tax of Rs. 1.68 Lakhs and total comprehensive profit for the half year ended 30th September, 2020 and cash flows (net outflow) of Rs.123.83 Lakhs for the period from 1stApril, 2020 to 30th September, 2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS


B. V. RAMANA REDDY
M. No: 026967 Partner



UIDN: 20026967AAAAHK7099

Place: Hyderabad
Date: 13.11.2020